KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Sales and Divestitures: 2010-2017

Historic Gains from Sales and Divestitures for Emergent BioSolutions (EBS) over the last 4 years, with Sep 2017 value amounting to $413,752.

  • Emergent BioSolutions' Gains from Sales and Divestitures was N/A to $413,752 in Q3 2017 from the same period last year, while for Sep 2017 it was $413,752, marking a year-over-year change of. This contributed to the annual value of $422,515 for FY2015, which is 17.04% up from last year.
  • According to the latest figures from Q3 2017, Emergent BioSolutions' Gains from Sales and Divestitures is $413,752, which was up 2.27% from $404,585 recorded in Q2 2016.
  • In the past 5 years, Emergent BioSolutions' Gains from Sales and Divestitures ranged from a high of $422,515 in Q4 2015 and a low of $291,619 during Q1 2013.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $405,970 (2015), whereas its average is $399,189.
  • Data for Emergent BioSolutions' Gains from Sales and Divestitures shows a peak YoY spiked of 1,434.84% (in 2013) over the last 5 years.
  • Over the past 5 years, Emergent BioSolutions' Gains from Sales and Divestitures (Quarterly) stood at $337,498 in 2013, then grew by 6.97% to $361,010 in 2014, then grew by 17.04% to $422,515 in 2015, then climbed by 2.74% to $404,585 in 2016, then reached $413,752 in 2017.
  • Its Gains from Sales and Divestitures was $413,752 in Q3 2017, compared to $404,585 in Q2 2016 and $353,117 in Q1 2016.